The High Price Of Bad Blood

It looks as though Baxter International Inc. is about to take another hit. Within weeks, it may be forced to reserve hundreds of millions of dollars to help redress one of the saddest accidents in medical history: the infection of thousands of hemophiliacs with HIV-tainted blood-clotting products.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.